aap Implantate AG

  • WKN: 506660
  • ISIN: DE0005066609
  • Land: Deutschland

Nachricht vom 21.04.2017 | 10:26

aap Implantate AG: aap concludes distribution agreement for LOQTEQ(R) Radius System with leading US medical technology company

DGAP-News: aap Implantate AG / Key word(s): Alliance/Agreement

21.04.2017 / 10:26
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces the conclusion of a distribution agreement for its LOQTEQ(R) Radius System with a worldwide leading US medical technology company.

According to the agreement, the LOQTEQ(R) Radius System is non-exclusively distributed in the entire territory of the United States. aap relies on a hybrid distribution strategy in North America. Distribution takes place both via distribution agents and through partnerships with global orthopaedic and medical technology companies.

The conclusion of the agreement represents further important progress in the aimed distribution focus on established markets such as North America, the DACH region and further European countries. The partnership with this customer will additionally support the dynamic development in North America and thus contribute to the further planned sales growth in this strategic core market.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de
 



21.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Timeless Hideaways GmbH begibt 7% Anleihe

Zins p.a.: 7%
Zinszahlung: vierteljährlich
Zeichnung: ab dem 30.06.2017
Laufzeit: 7 Jahre: 1.8.2017 bis 1.8.2024
Stückelung / Mindestanlage: 1.000,00 Euro
ISIN/WKN: DE000A2DALV1 /A2DALV

GBC im Fokus

Fintech-Spezialist für den afrikanischen Markt

Das Fintech-Unternehmen MyBucks S.A. bietet den Kunden aus der Sub-Sahara-Region durch den Einsatz moderner Technologien einen Zugang zu Finanzprodukten- und dienstleistungen. Hierbei handelt es sich in erster Linie um nicht besicherte Kredite, welche über Onlinekanäle beantragt und in Anspruch genommen werden. Die Grundlage für die Geschäftstätigkeit stellt die selbstentwickelte Technologie dar, wodurch Kunden innerhalb weniger Minuten eine Kreditentscheidung erhalten. Wir gehen von einer Fortsetzung der dynamischen Unternehmensentwicklung aus und haben einen fairen Wert von 26,70 € je Aktie und damit hohes Kurspotenzial ermittelt. Wir vergeben das Rating KAUFEN.

News im Fokus

Deutsche Börse AG: Anhörungsschreiben der Staatsanwaltschaft

18. Juli 2017, 14:59

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von Montega AG): Halten

18. Juli 2017